跳到正文
原文
Moderna· @moderna_tx · X·· 24 天前精选AI 评分78
AI 导读

Moderna与默沙东在ESMO 2026大会 Presidential Symposium 上公布了III期INTerpath-001试验的详细结果,该试验评估个体化新抗原疗法intismeran autogene(mRNA-4157或V940)联合帕博利珠单抗用于完全切除的IIB-IV期黑色素瘤患者。两家公司称这些结果为了解个体化癌症治疗的潜力提供了重要信息。

推荐理由

Moderna与默沙东公布III期INTerpath-001详细结果,读者可了解个体化新抗原疗法联合PD-1在黑色素瘤辅助治疗中的进展。

正文

With our partners at @Merck, we announced detailed results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized neoantigen therapy, in combination with pembrolizumab, in patients with completely resected stage IIB-IV melanoma.

Presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026, these findings offer important insights into the potential of individualized cancer treatment.

Read more: https://www.modernatx.com/recapping-the-phase-three-interpath-results

来源:Moderna · x.com